Cargando…
Efficacy of Methotrexate in patients with plaque type psoriasis
Objective: To assess the efficacy of Methotrexate in patients with plaque type psoriasis. Methods: This descriptive study was conducted in the department of Dermatology, Civil Hospital Karachi from September 2009 to March 2010. Seventy three patients between 18 to 50 years of age suffering from plaq...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publicaitons
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163230/ https://www.ncbi.nlm.nih.gov/pubmed/25225524 http://dx.doi.org/10.12669/pjms.305.4451 |
_version_ | 1782334765221806080 |
---|---|
author | Haider, Sabiqa Wahid, Zarnaz Najam-us-Saher, Riaz, Farzana |
author_facet | Haider, Sabiqa Wahid, Zarnaz Najam-us-Saher, Riaz, Farzana |
author_sort | Haider, Sabiqa |
collection | PubMed |
description | Objective: To assess the efficacy of Methotrexate in patients with plaque type psoriasis. Methods: This descriptive study was conducted in the department of Dermatology, Civil Hospital Karachi from September 2009 to March 2010. Seventy three patients between 18 to 50 years of age suffering from plaque type psoriasis with PASI score of >10 were included in the study after taking the informed consent. Oral methotrexate in a dose of 7.5 mg/week was given for 8 weeks. The data collected included demographic profile (age and gender), duration of disease, site of involvement, size of plaque, severity of plaque measured by Psoriasis Area and Severity Index (PASI) score before starting the treatment and at the end of treatment. Efficacy was labeled with a PASI score of ≤5 at the end of 8 weeks. Results: Out of 73 patients there were 45 (61.6%) males and 28 (38.4%) females. The mean ±SD age was 40.0±12.6 years. The mean baseline PASI score showed clear and comparable improvement from a mean ± SD PASI score of 14.8±4.2 to 4.9±4.3.Twenty nine (40%) patients had an almost complete remission during the 8 weeks of treatment. Partial remission was achieved in 44 (60%) patients. The clearance time for psoriasis ranged from 5-7 weeks (mean 6±0.89 weeks). Conclusion: Treatment with methotrexate for chronic plaque psoriasis brings satisfactory disease control and improved quality of life. |
format | Online Article Text |
id | pubmed-4163230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Professional Medical Publicaitons |
record_format | MEDLINE/PubMed |
spelling | pubmed-41632302014-09-15 Efficacy of Methotrexate in patients with plaque type psoriasis Haider, Sabiqa Wahid, Zarnaz Najam-us-Saher, Riaz, Farzana Pak J Med Sci Original Article Objective: To assess the efficacy of Methotrexate in patients with plaque type psoriasis. Methods: This descriptive study was conducted in the department of Dermatology, Civil Hospital Karachi from September 2009 to March 2010. Seventy three patients between 18 to 50 years of age suffering from plaque type psoriasis with PASI score of >10 were included in the study after taking the informed consent. Oral methotrexate in a dose of 7.5 mg/week was given for 8 weeks. The data collected included demographic profile (age and gender), duration of disease, site of involvement, size of plaque, severity of plaque measured by Psoriasis Area and Severity Index (PASI) score before starting the treatment and at the end of treatment. Efficacy was labeled with a PASI score of ≤5 at the end of 8 weeks. Results: Out of 73 patients there were 45 (61.6%) males and 28 (38.4%) females. The mean ±SD age was 40.0±12.6 years. The mean baseline PASI score showed clear and comparable improvement from a mean ± SD PASI score of 14.8±4.2 to 4.9±4.3.Twenty nine (40%) patients had an almost complete remission during the 8 weeks of treatment. Partial remission was achieved in 44 (60%) patients. The clearance time for psoriasis ranged from 5-7 weeks (mean 6±0.89 weeks). Conclusion: Treatment with methotrexate for chronic plaque psoriasis brings satisfactory disease control and improved quality of life. Professional Medical Publicaitons 2014 /pmc/articles/PMC4163230/ /pubmed/25225524 http://dx.doi.org/10.12669/pjms.305.4451 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Haider, Sabiqa Wahid, Zarnaz Najam-us-Saher, Riaz, Farzana Efficacy of Methotrexate in patients with plaque type psoriasis |
title | Efficacy of Methotrexate in patients with plaque type psoriasis |
title_full | Efficacy of Methotrexate in patients with plaque type psoriasis |
title_fullStr | Efficacy of Methotrexate in patients with plaque type psoriasis |
title_full_unstemmed | Efficacy of Methotrexate in patients with plaque type psoriasis |
title_short | Efficacy of Methotrexate in patients with plaque type psoriasis |
title_sort | efficacy of methotrexate in patients with plaque type psoriasis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163230/ https://www.ncbi.nlm.nih.gov/pubmed/25225524 http://dx.doi.org/10.12669/pjms.305.4451 |
work_keys_str_mv | AT haidersabiqa efficacyofmethotrexateinpatientswithplaquetypepsoriasis AT wahidzarnaz efficacyofmethotrexateinpatientswithplaquetypepsoriasis AT najamussaher efficacyofmethotrexateinpatientswithplaquetypepsoriasis AT riazfarzana efficacyofmethotrexateinpatientswithplaquetypepsoriasis |